Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,107.08 +5.00 (+0.45%)

Official Closing Price Updated: 7:00 PM EDT, Jun 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗

April 18, 2026

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

Via The Motley Fool

Topics Intellectual Property Stocks

Eli Lilly & Co (NYSE:LLY): A Growth Stock Showing Technical Setup for a Potential Breakout ↗

April 18, 2026

Via Chartmill

Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗

April 17, 2026

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.

Via The Motley Fool

Topics Artificial Intelligence

Is This the Biggest Game-Changer in Lilly's 150-Year History? ↗

April 17, 2026

The company's recent dip may be a buying opportunity.

Via The Motley Fool

Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake ↗

April 17, 2026

Eli Lilly obesity pill logs 1,390 U.S. scripts in first week, trailing Novo's oral Wegovy as competition in weight-loss drugs intensifies.

Via Benzinga

3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗

April 17, 2026

Via MarketBeat

Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. ↗

April 17, 2026

Eli Lilly's oral weight-loss drug, Foundayo, nabbed 1,390 prescriptions in its first week on the market, analysts said Friday.

Via Investor's Business Daily

Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗

April 17, 2026

The stock could have plenty of room to run from current levels.

Via The Motley Fool

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗

April 16, 2026

These companies boast significant upside potential.

Via The Motley Fool

Should You Forget CVS Health and Invest in a Purer Healthcare Play? ↗

April 16, 2026

There are other factors to consider before investing in this -- or any other -- healthcare company.

Via The Motley Fool

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson ↗

April 16, 2026

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.

Via Benzinga

Is This $6.3 Billion Deal a Game Changer for Eli Lilly? ↗

April 16, 2026

It's acquiring an asset with a very promising lead drug candidate.

Via The Motley Fool

Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar ↗

April 16, 2026

Eli Lilly Foundayo shows cardiovascular safety and stronger A1C, weight reduction, while the FDA flags liver risk, seeks additional data.

Via Benzinga

Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market ↗

April 16, 2026

Lilly's revenue has soared thanks to its obesity drugs.

Via The Motley Fool

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust ↗

April 15, 2026

And can Novo Nordisk catch up to its rival in the weight loss market?

Via The Motley Fool

Worried About a Stock Market Crash? These 3 Stocks Beat the S&P 500 by Wide Margins When It Nosedived in 2022, and They Could Do It Again ↗

April 15, 2026

During the last market crash, these stocks all generated positive returns -- one as high as 80%.

Via The Motley Fool

Topics Economy Stocks

Revolution Medicines (RVMD): The New Titan of the RAS Pathway (2026 Research Feature)

April 15, 2026

As of April 15, 2026, the biotechnology sector is witnessing a paradigm shift in precision oncology, spearheaded by Revolution Medicines, Inc. (Nasdaq: RVMD). Once considered a high-risk clinical-stage...

Via Finterra

Topics Initial Public Offering

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

Amazon (AMZN) Stock Is Up, What You Need To Know

April 14, 2026

What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 3.6% in the afternoon session after the company announced it ...

Via StockStory

Topics Artificial Intelligence

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

April 13, 2026

Via Get News

Topics Intellectual Property

After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock? ↗

April 13, 2026

In April, regulators approved Foundayo, Eli Lilly's GLP-1 pill for weight loss.

Via The Motley Fool

The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)

April 13, 2026

As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche...

Via Finterra

Topics Economy Initial Public Offering

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Topics Earnings Economy Intellectual Property

Eli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients ↗

April 13, 2026

Eli Lilly releases positive Phase 3 data for Jaypirca and Retevmo, with trial results supporting potential label expansion.

Via Benzinga

Eli Lilly & Co (NYSE:LLY) Presents a Prime Case for Affordable Growth Investing ↗

April 13, 2026

Eli Lilly (LLY) exemplifies the GARP strategy with strong growth, reasonable valuation relative to peers, and robust profitability for sustainable returns.

Via Chartmill

3 Mid-Cap Stocks Walking a Fine Line

April 13, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Via StockStory

1 Profitable Stock to Own for Decades and 2 That Underwhelm

April 13, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

The Post-Ozempic Economy? 2 Industries Bracing for a Slimmer, Less Hungry America ↗

April 12, 2026

The use of weight-loss drugs is growing like crazy and changing the entire consumer economy along with it.

Via The Motley Fool

Topics Artificial Intelligence Economy

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire ↗

April 11, 2026

And it's not too late to get in on the action.

Via The Motley Fool

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.